Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise ...

Verve Therapeutics, a clinical-stage biotechnology company, focuses on developing gene editing medicines for cardiovascular disease treatment, making it a strategic acquisition for Eli Lilly’s ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing therapies for cardiovascular diseases, in a deal valued at up to $1.3 billion.